A minimalist fragment approach for the design of natural-product-like synthetic scaffolds.

Chemistry groups involved in drug discovery continue to devote their efforts to improving compound design with the aim of identifying new drug candidates. Many crucial factors must be considered, including: chemical stability, synthetic difficulty, chemical complexity and diversity, ADMET properties, cost, chemical novelty and intellectual property issues, and 'biological appropriateness'. With regard to the latter point, natural products offer an outstanding source of biologically active molecules that provide many useful features that enable us to design innovative, biologically biased, synthetic compounds. This article outlines the recent approaches in this area and suggests a simple metric to assess synthetic compounds for natural product likeness.

[1]  Peter Ertl,et al.  Cheminformatics analysis of natural products: lessons from nature inspiring the design of new drugs. , 2008, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[2]  Sivaraman Dandapani,et al.  Current strategies for diversity-oriented synthesis. , 2010, Current opinion in chemical biology.

[3]  F. Petersen,et al.  Natural compounds as drugs , 2008 .

[4]  A. Schuffenhauer,et al.  Charting biologically relevant chemical space: a structural classification of natural products (SCONP). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Ricardo Macarron,et al.  Enhancements of screening collections to address areas of unmet medical need: an industry perspective. , 2010, Current opinion in chemical biology.

[6]  Peter Ertl,et al.  Natural Product-likeness Score and Its Application for Prioritization of Compound Libraries , 2008, J. Chem. Inf. Model..

[7]  Anwar Rayan,et al.  Physicochemical Properties of Natural Based Products versus Synthetic Chemicals , 2010 .

[8]  Gemma L Thomas,et al.  Natural product-like synthetic libraries. , 2011, Current opinion in chemical biology.

[9]  Zoya Titarenko,et al.  BioCores: identification of a drug/natural product-based privileged structural motif for small-molecule lead discovery , 2010, Molecular Diversity.

[10]  Andreas Bender,et al.  Plate-Based Diversity Selection Based on Empirical HTS Data to Enhance the Number of Hits and Their Chemical Diversity , 2009, Journal of biomolecular screening.

[11]  Herbert Waldmann,et al.  Natural product guided compound library development. , 2002, Current medicinal chemistry.

[12]  Gisbert Schneider,et al.  Scaffold diversity of natural products: inspiration for combinatorial library design. , 2008, Natural product reports.

[13]  C. Bewley,et al.  Synthetic macrolides that inhibit breast cancer cell migration in vitro. , 2007, Journal of the American Chemical Society.

[14]  Simon J F Macdonald,et al.  Factors determining the selection of organic reactions by medicinal chemists and the use of these reactions in arrays (small focused libraries). , 2010, Angewandte Chemie.

[15]  Miklos Feher,et al.  Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..

[16]  G. Rishton,et al.  Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening. , 2008, Current opinion in chemical biology.

[17]  W Patrick Walters,et al.  What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.

[18]  Thomas Henkel,et al.  Statistical Investigation into the Structural Complementarity of Natural Products and Synthetic Compounds. , 1999, Angewandte Chemie.

[19]  Tudor I. Oprea,et al.  Novel chemical space exploration via natural products. , 2009, Journal of medicinal chemistry.

[20]  G. Schneider,et al.  Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. , 2001, Journal of combinatorial chemistry.

[21]  David R Cheshire How well do medicinal chemists learn from experience? , 2011, Drug discovery today.

[22]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[23]  A. M. Boldi,et al.  Libraries from natural product-like scaffolds. , 2004, Current opinion in chemical biology.

[24]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[25]  Derek S. Tan,et al.  Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective. , 2010, Current opinion in chemical biology.

[26]  R. Sakai,et al.  Regioselective Domino Metathesis of Unsymmetrical 7-Oxanorbornenes with Electron-Rich Vinyl Acetate toward Biologically Active Glutamate Analogues. , 2009, European journal of organic chemistry.

[27]  Kevin Burgess,et al.  Minimalist and universal peptidomimetics. , 2011, Chemical Society reviews.

[28]  G. Bemis,et al.  A minimalist approach to fragment‐based ligand design using common rings and linkers: Application to kinase inhibitors , 2004, Proteins.

[29]  A. Wettstein Fortschritte der Arzneimittelforschung , 1960, Experientia.

[30]  Daniel Yohannes,et al.  Diversity-oriented synthesis of a cytisine-inspired pyridone library leading to the discovery of novel inhibitors of Bcl-2. , 2009, Bioorganic & medicinal chemistry letters.